Analysis: Inside the ARM-Xilinx deal
Richard Nass, EETimes
(10/22/2009 8:12 PM EDT)
There's a lot that's not being said about the deal announced earlier this week by ARM and Xilinx. What is known is that Xilinx has licensed ARM's Cortex processor IP, and that the two companies are developing next-generation AMBA interconnect technology. But if you read between the lines, you can see where the partnership is likely headed. First and foremost, what took so long? I wondered for years why Xilinx never adopted the ARM architecture like many of its competitors. The answer lies in the development of the next-generation AMBA bus specification, which Xilinx is calling "an optimized interconnect standard for FPGAs." Xilinx designers likely felt that without this new development, they couldn't get the maximum potential from the ARM architecture, and therefore had no desire to be a "me-too" FPGA vendor.
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |
Related News
- Analysis: In $2.5B Deal, Qualcomm & CSR Mesh
- Analysis: Synopsys-Coverity Deal Final
- Apache Design's Totem Software Adopted by Fujitsu Semiconductor for Power Noise and Reliability Analysis
- MunEDA WiCkeD Tool Suite to Enhance Circuit Analysis, Performance and Yield Optimization Has Been Selected by Toshiba
- Analysis: Why ARM-AMD makes sense
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design